Technical Analysis for ADAP - Adaptimmune Therapeutics plc

Grade Last Price % Change Price Change
F 4.93 -2.18% -0.11
ADAP closed down 2.18 percent on Friday, April 16, 2021, on 87 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical ADAP trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish -2.18%
20 DMA Resistance Bearish -2.18%
180 Bearish Setup Bearish Swing Setup -2.18%
BB Squeeze Ended Range Expansion -2.18%
Bollinger Band Squeeze Range Contraction -2.76%
Narrow Range Bar Range Contraction -2.76%
Inside Day Range Contraction -2.76%
MACD Bearish Signal Line Cross Bearish -0.80%
Bollinger Band Squeeze Range Contraction -0.80%
20 DMA Resistance Bearish -2.38%
Older End-of-Day Signals for ADAP ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Adaptimmune Therapeutics plc Description

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets in the form of peptides, which are short sequences of amino acids; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company's lead product candidate includes NY-ESO, a cancer antigen, which is in Phase I/II clinical trials for the treatment of patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer, and esophageal cancer, as well as for non-small cell lung cancer. It is also developing MAGE A-10 TCR that is in preclinical stage for the treatment of breast and lung cancer, and other solid tumors, as well as a TCR therapeutic candidate directed to Alpha Fetoprotein. The company was founded in 2014 and is headquartered in Abingdon, the United Kingdom.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Acid Solid Tumors Immunotherapy Cancer Treatments Cancer Immunotherapy Virotherapy Small Cell Lung Cancer Ovarian Cancer Melanoma Non Small Cell Lung Cancer Acids Multiple Myeloma Peptides Sarcoma Novi Hematological Malignancies Oncolytics Biotech Adoptive Cell Transfer Immunotherapy Product Tumors Of The Hematopoietic And Lymphoid Tissues Cancer Immunotherapy Product Amino Acids Cancer Immunotherapy Products Immunotherapy Products Breast And Lung Cancer Esophageal Cancer

Is ADAP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.4
52 Week Low 3.2
Average Volume 858,011
200-Day Moving Average 6.57
50-Day Moving Average 5.57
20-Day Moving Average 5.18
10-Day Moving Average 5.11
Average True Range 0.37
ADX 10.56
+DI 20.82
-DI 22.02
Chandelier Exit (Long, 3 ATRs ) 4.94
Chandelier Exit (Short, 3 ATRs ) 5.86
Upper Bollinger Band 5.62
Lower Bollinger Band 4.74
Percent B (%b) 0.21
BandWidth 16.91
MACD Line -0.13
MACD Signal Line -0.12
MACD Histogram -0.0077
Fundamentals Value
Market Cap 763.06 Million
Num Shares 155 Million
EPS -0.97
Price-to-Earnings (P/E) Ratio -5.10
Price-to-Sales 200.53
Price-to-Book 2.02
PEG Ratio 0.11
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.26
Resistance 3 (R3) 5.25 5.14 5.20
Resistance 2 (R2) 5.14 5.06 5.14 5.18
Resistance 1 (R1) 5.04 5.01 4.98 5.04 5.17
Pivot Point 4.92 4.92 4.90 4.93 4.92
Support 1 (S1) 4.82 4.84 4.76 4.82 4.69
Support 2 (S2) 4.71 4.79 4.71 4.68
Support 3 (S3) 4.60 4.71 4.66
Support 4 (S4) 4.60